menu

BIO CATEGORY: ADVISOR

Stefan Herm

Stefan Herm is a global healthcare IT industry expert and entrepreneur. Following his role as Managing Director of GSD, a Berlin-based enterprise IT company he successfully sold to Siemens, he had executive leadership roles at both McKesson and Nuance. He currently works with McKinsey as an external advisor for Healthcare IT and has done consulting in large hospital IT tenders and implementations in the Middle East. He also works throughout Central and Eastern Europe with Penta Hospitals International, a large private hospital chain, developing its IT strategy.

READ MORE
Michael Hadjisavas

Michael Hadjisavas has been a leader in the Life Sciences, Applied Markets and Diagnostics industries for over 20 years, including 10 years focusing on genomics, translational research, bioinformatics and molecular diagnostics. He currently serves as VP of Assay Technologies, Head of Life Sciences Portfolio Strategy and previously as VP Clinical Genomics and Bioinformatics at QIAGEN, Inc. His prior positions include executive and senior leadership roles at: Abcam PLC, Gen-Probe/Hologic, Life Technologies/Thermo, and Sigma-Aldrich. His commercial and operational experience includes portfolio responsibilities for systems, consumables and software for the research, pharmaceutical, and diagnostics segments. He has also held numerous strategic advisory roles...

READ MORE
Russ Clark

Russ Clark is a lawyer by training and has more than twenty-five years of experience in cancer related endeavors. He has broad and deep experience in cancer clinical trials as well as information technology to support cancer care and cancer research. Russ has founded or co-founded a number of successful cancer-related companies working with academic cancer centers, community hospitals, oncology practices, payers and biopharmaceutical companies. He has worked in the cancer genomics field since 1998. His network includes many oncology thought leaders who he has worked with on a variety of projects over the years.

READ MORE
Andrew Litt

Andrew Litt is CEO of Cornice Health Ventures, LLC., which helps others acquire and collaborate with healthcare service companies.  Dr. Litt is also an Operating Partner with The Vistria Group, a private equity firm. Until 2014, he was the Chief Medical Officer for Dell’s Healthcare and Life Sciences division. Prior to that, Dr. Litt was Executive Vice President and Vice Dean at the NYU Langone Medical Center, where he was responsible for managing all activities and strategy across the institution. Dr. Litt helped found and was Board Chair of CareCore National, which provides utilization and quality management program. He also was...

READ MORE
Alice Jacobs

Alice Jacobs is a physician entrepreneur, advisor and investor. She co-founded IMDx while completing Harvard Medical School. Raising $40M in funding and closing almost another $40M in strategic deals the company had five FDA cleared and eight CE marked products before being sold to Qiagen. Alice has been an advisor to Third Rock Ventures, MIT and GE Healthcare Ventures. She holds multiple patents in personalized medicine and has been honored with numerous awards including a “Top 50 Innovators” by the World Economic Forum.

READ MORE
Anup Raina

Anup Raina is a serial entrepreneur and experienced healthcare executive. He is the co-founder of Reads for Rads, Inc., which provides expert remote teleradiology interpretation services. He is also a business associate at the Drexel University College of Medicine. Anup was previously COO for Wipro’s Global Healthcare Information Technology business (which was acquired from GE), and he also worked for Siemens Healthcare in Corporate Strategy and Consulting. Anup has extensive business connections in India and is fluent in German, English, Hindi and Kashmiri.

READ MORE
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER